Bristol-Myers Squibb Company (BMY)
| Market Cap | 135.84B +41.4% |
| Revenue (ttm) | 49.19B +3.1% |
| Net Income | 9.28B +83.8% |
| EPS | 4.54 +82.7% |
| Shares Out | 2.04B |
| PE Ratio | 14.74 |
| Forward PE | 10.43 |
| Dividend | $2.52 (3.79%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 2,404,452 |
| Open | 66.77 |
| Previous Close | 66.95 |
| Day's Range | 66.19 - 66.84 |
| 52-Week Range | 42.52 - 68.64 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 66.21 (-0.44%) |
| Earnings Date | Jul 30, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $66.21, which is a decrease of -0.44% from the latest price.
News
Bristol Myers Squibb Stock (BMY) Looks Healthier After Ditching Blood Cancer Partner
Shares in biopharmaceutical stock Bristol Myers Squibb ($BMY) remained healthy today despite scrapping its partnership with California-based blood cancer startup Cellares. According to a Reuters artic...
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday...
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
Atrium Therapeutics (RNA) announced it has earned another $15M milestone payment from Bristol Myers Squibb (BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology...
Court revives suit against Bristol Myers over delayed drug, Reuters reports
A federal appeals court has revived a $6.7B lawsuit against Bristol Myers (BMY) alleging delayed drug approvals harmed former Celgene shareholders, ruling that UMB Bank (UMBF) could represent them as…
Bristol Myers’ first CELMoD myeloma therapy granted accelerated FDA approval
Bristol Myers (BMY) announced that the FDA has approved Zenbexus – iberdomide – in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multip...
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.
US FDA approves Bristol Myers' blood cancer treatment
The U.S. FDA on Thursday approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the he...
Lawsuit against Bristol Myers over delayed cancer drug is revived
A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs...
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutic...
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
AstraZeneca (AZN) CEO Pascal Soriot had been quietly pursuing a transformative deal and held serious talks with Bristol Myers (BMY) over a potential mostly stock-based acquisition at a premium, despit...
Bristol Myers announces $2.3B campus in Houston, Texas
Bristol Myers (BMY) Squibb announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3B investment designed ...
Bristol Myers to build $2.3 billion manufacturing site in Houston
Drugmaker Bristol Myers Squibb on Monday said it will spend about $2.3 billion to build a new manufacturing facility in Houston, Texas, part of a previously announced $40 billion commitment to inves...
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas.
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol-Myers Squibb ($BMY) fell by more than 3%. This came…
Bristol Myers upgraded to Buy from Hold at Argus
Argus analyst Jasper Hellweg upgraded Bristol Myers (BMY) to Buy from Hold with a $75 price target Bristol Myers is showing signs of a turnaround as growth products and new…
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
AstraZeneca (AZN) and Bristol Myers (BMY) are not engaged in merger discussions, ending speculation around a potential $400B pharmaceutical combination, Reuters’ Maggie Fick and Sabrina Valle report. ...
Schrodinger announces collaboration, software agreement with Bristol Myers
Schrodinger (SDGR) announced a strategic agreement with Bristol Myers Squibb (BMY) to deploy Bunsen, Schrodinger’s agentic AI co-scientist, within its research organization. The new agreement signific...
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a moot...
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
AstraZeneca’s (AZN) merger talks with Bristol Myers (BMY) remain active, Liz Hoffman of Semafor reports. A potential deal would move AstraZeneca’s revenues further away from the UK and Europe and…
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth would be diluted by two percentage points,...
Astra Buying Bristol Makes No Sense, Fazeli Says
AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers.